We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Loxo Oncology, Inc. (NASDAQGM: LOXO) to Eli Lilly and Company (NYSE: LLY) for $235 per share.
The Loxo Oncology merger investigation concerns whether the Board of Loxo Oncology breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Eli Lilly and Company is underpaying for Loxo Oncology shares, thus unlawfully harming Loxo Oncology shareholders
To receive more information, please fill out the form.